Profile
I am a health economist at the Health Economics and Policy Research Unit within the Wolfson Institute of Population Health, Queen Mary University of London. I hold a PhD from the University of Melbourne and have specialised expertise in the health economics of genomic and precision medicine. My research has contributed towards shaping both national and international discussions and policies aimed at ensuring the equitable, effective, and affordable delivery of genomic technologies and related treatments. I am passionate about advancing health economic policy research using robust, evidence-based economic evaluations to support regulatory and policy decisions around these emerging technologies.
I completed my PhD at the University of Melbourne in 2023 where my thesis focused on several studies examining the health economic impact of genome sequencing in guiding clinical care for blood cancer patients. Prior to this, I was a Research Fellow at Cancer Health Services Research, University of Melbourne where I led multiple research projects on the economics and genomics of cancer. I also served as an evaluator with the Melbourne Health Technology and Value Assessment Collaboration, conducting comprehensive assessments of new pharmaceutical health technology submissions for the Pharmaceutical Benefits Advisory Committee (PBAC) at the Department of Health and Aged Care.
Research
Research Interests:
I specialise in the health economics of genomic and precision medicine with a keen focus on evaluating the cost-effectiveness and economic impact of genomic technologies. My research focuses on how the application of genomics can transform patient care and lead to changes in healthcare spending, resource management, and access to innovative treatments. I am also interested in the broader economic implications of genomics on a societal level. Through my work, I aim to support complex policy decisions regarding the implementation and funding of these technologies within healthcare systems.
Publications
Featured publications
Vu, M., Degeling, K., Westerman, D., IJzerman, M.J. (2024). Scenario analysis and multi-criteria decision analysis to explore alternative reimbursement pathways for whole genome sequencing for blood cancer patients. Journal of Cancer policy. 41, 100501. https://doi.org/10.1016/j.jcpo.2024.100501.
Vu, M., Degeling, K., Ryland L.G., Hofman, O., Ng, A.P., Westerman, D., IJzerman, M. (2024). Economic impact of whole genome sequencing and whole transcriptome sequencing versus routine diagnostic molecular testing to stratify patients with B-cell acute lymphoblastic leukemia. The Journal of Molecular Diagnostics. 26(8):673-684. https://doi.org/10.1016/j.jmoldx.2024.04.006.
Vu, M., Degeling, K., Thompson, E.R., Westerman, D., IJzerman, M.J. (2024). Cost effectiveness of molecular diagnostic testing algorithms for the treatment selection of frontline ibrutinib for patients with chronic lymphocytic leukemia in Australia. Applied Health Economics and Health Policy.22:107–122. https://doi.org/10.1007/s40258-023-00826-4
Vu, M., Degeling, K., Thompson, E.R., Blombery, P., Westerman, D., IJzerman, M.J. (2022). Health economic evidence for the use of molecular biomarker tests in hematological malignancies: a systematic review. European Journal of Hematology. 108(6):469-485.https://doi.org/10.1111/ejh.13755
Vu, M., Degeling, K., Martyn, M., Lynch, E., Chong, B., Gaff. C., IJzerman M. (2020). Evaluating the resource implications of different service delivery models for offering additional genomic findings. Genetics in Medicine, 23, 606-613. https://doi.org/10.1038/s41436-020-01030-8
